42 followers
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. https://t.co/9XR6gC9RDb https://t.co/YYW6jGkM3I
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. https://t.co/9XR6gC9RDb https://t.co/YYW6jGkM3I